Larimar Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Larimar Therapeutics, Inc. on April 6, 2023, reporting an event that occurred on April 3, 2023. The Company is a Delaware corporation with its principal executive offices in Bala Cynwyd, Pennsylvania, and its common stock trades on the NASDAQ Global Market under the symbol "LRMR".
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of Peter Barrett, Ph.D., from the Board of Directors. Dr. Barrett tendered his resignation to be effective on May 9, 2023, coinciding with the Company's 2023 Annual Meeting of Stockholders. The Company explicitly stated that the resignation did not result from any disagreement with the Company regarding operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to expressing gratitude for Dr. Barrett's service and confirming the amicable nature of his departure.
Key Facts for Investor Verification
- Dr. Peter Barrett's resignation from the Board is effective May 9, 2023.
- The departure was not caused by any disagreement with the Company.
- The resignation will be finalized at the 2023 Annual Meeting of Stockholders.
- No financial metrics or operational updates are included in this specific filing.